GSK eyes nasal polyps use for Nucala after trial successGlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation Share XGSK eyes nasal polyps use for Nucala after trial successhttps://pharmaphorum.com/news/gsk-eyes-nasal-polyps-use-for-nucala-after-trial-success/
Trump pledges access to malaria drug chloroquine for COVID-19President Donald Trump thrust a decades old malaria drug called chloroquine into the forefront of efforts to treat Share XTrump pledges access to malaria drug chloroquine for COVID-19https://pharmaphorum.com/news/trump-pledges-access-to-malaria-drug-chloroquine-for-covid-19/
After rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival AjovySeveral months after turning down NHS funding for Novartis’ CGRP inhibitor Aimovig for migraine prevention, NICE has backed Share XAfter rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival Ajovyhttps://pharmaphorum.com/news/novartis-aimovig-for-migraine-nice-backs-teva-rival/
FDA approves ‘potential blockbuster’ migraine jab from LundbeckThe FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs Share XFDA approves ‘potential blockbuster’ migraine jab from Lundbeckhttps://pharmaphorum.com/news/fda-approves-potential-blockbuster-migraine-jab-from-lundbeck/
Teva draws blank in phase 3 Tourette Syndrome trialTeva’s late stage trials of a potential drug for Tourette Syndrome have drawn a blank, just when the Share XTeva draws blank in phase 3 Tourette Syndrome trialhttps://pharmaphorum.com/news/teva-draws-blank-in-phase-3-tourette-syndrome-trial/
Warren Buffet shocks Wall Street with Biogen gambleBiogen is trying to resurrect two failed trials of its Alzheimer’s drug aducanumab – and superstar investor Warren Share XWarren Buffet shocks Wall Street with Biogen gamblehttps://pharmaphorum.com/news/warren-buffet-shocks-wall-street-with-biogen-gamble/
COVID-19 could disrupt supplies of cheap generics, analysts warnAn extended COVID-19 coronavirus outbreak could impact on supplies of generic drugs that many health systems rely on Share XCOVID-19 could disrupt supplies of cheap generics, analysts warnhttps://pharmaphorum.com/news/covid-19-could-disrupt-supplies-of-cheap-generics-moodys/
First Rituxan biosimilar Truxima set to make its debut in USBiosimilar competition to Roche’s big-selling Rituxan has arrived in the US, with Teva gearing up to launch its Share XFirst Rituxan biosimilar Truxima set to make its debut in UShttps://pharmaphorum.com/news/first-rituxan-biosimilar-truxima-set-to-makes-its-debut-in-us/
Teva’s strategy for multichannel engagementTeva has a simple strategy for multichannel customer relationship management (CRM) and at its heart is the alignment Share XTeva’s strategy for multichannel engagementhttps://pharmaphorum.com/sales-marketing/tevas-strategy-for-multichannel-engagement/
